Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product.
BAY 81-8973, a new full length recombinant FVIII product, has been developed for prophylaxis and on-demand therapy in patients with hemophilia A. LEOPOLD II was a phase 2/3 study comparing prophylaxis versus on-demand treatment with BAY 81-8973. The analysis herein evaluated the clinical profile in Japanese subjects enrolled in LEOPOLD II. The LEOPOLD II was an open-label randomized crossover study. Our analysis evaluated the efficacy using the annualized bleeding rate, safety, and pharmacokinetics in Japanese subjects with severe hemophilia A enrolled in LEOPOLD II. The median annualized bleeding rate was 59.9/year in the on-demand group and 1.9/year in the prophylaxis group for Japanese subjects. There were no study drug-related adverse events in the Japanese subjects. None of the subjects developed FVIII inhibitors. There were no apparent clinical differences in efficacy, safety, and pharmacokinetics between the Japanese and the non-Japanese subjects. Data for the Japanese subjects showed annualized bleeding rates to be remarkably lower in the prophylaxis group compared to the on-demand group and that BAY 81-8973 exhibited a good safety profile and tolerability. These results were similar for the non-Japanese subjects. The results support adoption of BAY 81-8973 for treatment of Japanese subjects with severe hemophilia A.
Hiroshima University Hospital, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8511, Japan. teruchan@hiroshima-u.ac.jp.
Teruhisa
http://orcid.org/0000-0002-6959-6346
T
Fujii
Ogikubo Hospital, Suginami-ku, Tokyo, Japan.
Hideji
H
Hanabusa
Nara Medical University Hospital, Kashihara, Nara, Japan.
Midori
M
Shima
Bayer Yakuhin, Ltd., Kita-ku, Osaka, Japan.
Takeshi
T
Morinaga
Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan.
Katsuyuki
K
Fukutake
D000293:Adolescent; D000328:Adult; D000368:Aged; D044466:Asian People; D002648:Child; D018592:Cross-Over Studies; D005169:Factor VIII / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D006470:Hemorrhage / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D011292:Premedication / Q000379:methods*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII
Hemophilia A; On-demand therapy; Prophylaxis; Recombinant factor VIII